Friday, November 7: Bliss GVS Pharma Ltd reported a modest performance for the quarter ended September 30, 2025, with revenue and net profit showing slight growth year-on-year, while operating margins weakened due to higher costs.
The company’s consolidated revenue from operations increased 4.8% YoY to Rs 245.86 crore, compared to Rs 234.1 crore in the same quarter last year. However, EBITDA fell 20% YoY, with the EBITDA margin declining to 13% from 18.3% a year ago, reflecting pressure on operating efficiency.
Bliss GVS reported a net profit of Rs 25.69 crore, up 2.5% from Rs 25.08 crore in Q2 FY25. Profit before tax rose to Rs 40.63 crore from Rs 35.70 crore, supported by steady sales and controlled financing costs.
Quarterly Financial Performance (Consolidated)
| Particulars (Rs in crore) | Q2 FY26 | Q2 FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations | 245.86 | 234.10 | +4.8% |
| Total Income | 254.10 | 224.45 | +13.2% |
| EBITDA | 40.73 | 51.10 | -20.3% |
| EBITDA Margin | 13.0% | 18.3% | -530 bps |
| Profit Before Tax | 40.63 | 35.70 | +13.8% |
| Net Profit | 25.69 | 25.08 | +2.5% |
For the first half of FY26, total income grew 23.6% YoY to Rs 511.02 crore, while net profit stood at Rs 72.95 crore, up 52.6% from Rs 47.79 crore in H1 FY25. Despite revenue growth, the margin compression suggests short-term cost challenges in material sourcing and manufacturing.
Disclaimer:
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
